InfectoPharm invests in AudioCure

InfectoPharm joins AudioCure Pharma as a new investor. Together with MED-EL and High-Tech Gründerfonds, the development of AC102 is to be further advanced

Heppenheim/Berlin, February 13, 2025 - Berlin-based biotech startup AudioCure Pharma is receiving fresh investment to further advance the clinical development of its drug candidate AC102. The medium-sized pharmaceutical company InfectoPharm, which specializes in the ENT sector, is leading the new financing round and strengthening the existing investor group around MED-EL and High-Tech Gründerfonds (HTGF). The aim of the cooperation is to develop an effective drug treatment for sudden deafness - a disease for which there is currently no approved therapy.

Strategic partnership for innovative drug development

The collaboration between AudioCure and InfectoPharm goes beyond mere financial participation. As an experienced player in ENT pharmaceuticals, InfectoPharm brings in-depth scientific and commercial expertise to the table.

Our partners complement each other perfectly - by joining forces, we can drive the development of AC102 forward in an even more targeted manner. InfectoPharm's many years of experience are a valuable addition for us.

Dr. Reimar Schlingensiepen, Managing Director of AudioCure

AC102: Hope for patients with sudden deafness

The drug candidate AC102 has already shown promising results in preclinical studies. In hearing loss models, it was able to restore hearing almost completely, outperforming conventional corticosteroid therapies. After confirming the safety and tolerability of the drug in a Phase 1 study, a Phase 2 study is currently underway to evaluate the efficacy of AC102 in patients with sudden hearing loss in several European countries.

We know how stressful sudden hearing loss is for those affected. AC102 could provide a real treatment option for the first time - we are proud to support this promising project with our knowledge and funding.

Philipp Zöller, Managing Partner of InfectoPharm

AudioCure Pharma GmbH, based in Berlin, is a biotech company focusing on innovative therapies for hearing disorders. In addition to the development of AC102, the company is working on active substances for the treatment of tinnitus and to support residual hearing in cochlear implant recipients.

An important step for the treatment of hearing loss

With the participation of InfectoPharm, AudioCure gains a strong partner that not only provides financial resources, but also brings in-depth expertise in the field of ENT pharmaceuticals. If AC102 also proves its efficacy in the ongoing studies, this could mean a breakthrough in the treatment of hearing loss.